SALEM — With a third of the session gone, the Oregon Legislature has 4,000 bills on its plate, with House Republicans using a parliamentary slow-down to delay legislation already running
Legislative logjam rolls on toward do-or-die day Friday gazettetimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazettetimes.com Daily Mail and Mail on Sunday newspapers.
February 22nd, 2021 in Featured and Health. Closed
Dr. Rahel Nardos is connecting the University of Minnesota with low-resource locations to improve healthcare access. (Courtesy photo)
Minnesota Monthly Magazine
What do Minnesota’s Indigenous, immigrant, African American, and refugee communities have in common with women in low-resource countries around the world? They’re all chronically underserved by healthcare providers. So says Rahel Nardos, MD, the new director of global women’s health at the University of Minnesota’s Center for Global Health and Social Responsibility (CGHSR). And she aims to change that.
Nardos was born in Addis Ababa, Ethiopia. She came to the U.S. for college on a scholarship, then attended Yale Medical School, where she met her husband, Damien Fair, who was pursuing his PhD in neuroscience. They moved to Addis Ababa after completing their studies, where Nardos cared for women with obstetric fistulas, a devastating condition i
Many restaurants in the Portland, Oregon area depend on deals to provide health workers with food because they are not permitted to be fully open during the coronavirus health crisis.
email article
An FDA advisory committee turned thumbs down on Becton Dickinson s Lutonix 014 drug-coated balloon (DCB) for peripheral artery disease (PAD) during a virtual meeting on Wednesday.
Circulatory System Devices Panel members voted 14-3 (with one abstention) that the benefits of the investigational angioplasty catheter do not outweigh its risks as a treatment for patients with critical limb ischemia (CLI) who have obstructive de novo or non-stented restenotic lesions in below-the-knee (BTK) arteries.
Committee members were largely unconvinced that the Lutonix DCB was supported by adequate efficacy data.
In the pivotal Lutonix BTK IDE trial, the device showed a 10.5% absolute advantage in the primary efficacy endpoint (combined primary patency and limb salvage) at 6 months that was not significant under Bayesian analysis. Such improvement, if any, vanished by 12 months, and the endpoint started to favor the regular percutaneous transluminal angioplasty (PTA) arm by